Back

Neurologic sequalae of COVID-19 are determined by immunologic imprinting from previous Coronaviruses.

Spatola, M.; Nziza, N.; Deng, Y.; Jung, W.; Yuan, D.; Dinoto, A.; Bozzetti, S.; Chiodega, V.; Ferrari, S.; Lauffenburger, D. A.; Mariotto, S.; Alter, G.

2022-11-10 allergy and immunology
10.1101/2022.11.07.22282030
Show abstract

Coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global public health emergency. Although SARS-CoV-2 is primarily a respiratory pathogen, extra-respiratory organs, including the central nervous system (CNS), can also be affected. Neurologic symptoms have been observed not only during acute SARS-CoV-2 infection, but also at distance from respiratory disease, also known as long-COVID or neurological post-acute sequelae of COVID-19 (neuroPASC). The pathogenesis of neuroPASC is not well understood, but hypotheses include SARS-CoV-2-induced immune dysfunctions, hormonal dysregulations, and persistence of SARS-CoV-2 reservoirs. In this study, we used a high throughput systems serology approach to dissect the humoral response to SARS-CoV-2 (and other common Coronaviruses - 229E, HKU1, NL63, OC43) in the serum and cerebrospinal fluid (CSF) from 112 infected individuals who developed or did not develop neuroPASC. Unique SARS-CoV-2 humoral profiles were observed in the CSF of neuroPASC. All antibody isotypes (IgA, IgM, IgA) and subclasses (IgA1-2; IgG1-4) were detected in serum, whereas CSF was characterized by focused IgG1 (and absence of IgM). These data argue in favor of compartmentalized brain-specific responses against SARS-CoV-2 through selective transfer of antibodies from the serum to the CSF across the blood-brain-barrier, rather than intrathecal synthesis, where more diversity in antibody classes/subclasses would be expected. Moreover, compared to individuals who did not develop post-acute neurological complications following infection (n=94), those with neuroPASC (n=18) exhibited attenuated systemic antibody responses against SARS-CoV-2, characterized by decreased capacity to activate antibody-dependent complement deposition (ADCD), NK cell activation (ADNKA) and to bind Fc{gamma} receptors. However, surprisingly, neuroPASC showed significantly expanded antibody responses to other common Coronaviruses, including 229E, HKU1, NL63, and OC43. This biased humoral activation across coronaviruses was particularly enriched in neuroPASC individuals with poor outcome, suggesting an original antigenic sin (or immunologic imprinting), where pre-existing immune responses against related viruses shape the response to current infection, as a key prognostic marker of neuroPASC disease. Overall, these findings point to a pathogenic role for compromised anti-SARS-CoV-2 responses in the CSF, likely resulting in incomplete virus clearance from the brain and persistent neuroinflammation, in the development of post-acute neurologic complications of SARS-CoV-2 infection.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
based on 483 papers
Top 5%
12.7%
2
Frontiers in Immunology
based on 140 papers
Top 0.6%
10.2%
3
Nature Immunology
based on 14 papers
Top 0.1%
10.2%
4
Brain
based on 69 papers
Top 1%
7.6%
5
Science Immunology
based on 15 papers
Top 0.1%
4.5%
6
Cell
based on 28 papers
Top 0.3%
4.5%
7
Cell Reports Medicine
based on 49 papers
Top 0.8%
3.9%
50% of probability mass above
8
Allergy
based on 13 papers
Top 0.7%
3.0%
9
The Journal of Immunology
based on 19 papers
Top 0.5%
2.8%
10
Journal of Clinical Investigation
based on 50 papers
Top 0.7%
2.8%
11
The Journal of Infectious Diseases
based on 137 papers
Top 3%
2.8%
12
Immunity
based on 11 papers
Top 0.3%
2.5%
13
eLife
based on 262 papers
Top 11%
2.4%
14
Journal of Clinical Immunology
based on 11 papers
Top 0.2%
1.9%
15
Journal of Experimental Medicine
based on 10 papers
Top 0.5%
1.6%
16
Clinical Immunology
based on 12 papers
Top 0.9%
1.3%
17
Clinical Infectious Diseases
based on 219 papers
Top 16%
1.3%
18
Cell Reports
based on 25 papers
Top 1%
1.3%
19
Science Translational Medicine
based on 40 papers
Top 3%
1.3%
20
mSphere
based on 27 papers
Top 1%
1.3%
21
PLOS ONE
based on 1737 papers
Top 92%
1.3%
22
Molecular Psychiatry
based on 84 papers
Top 6%
0.8%
23
Communications Biology
based on 36 papers
Top 4%
0.8%
24
JCI Insight
based on 63 papers
Top 6%
0.8%
25
eBioMedicine
based on 82 papers
Top 9%
0.7%
26
npj Vaccines
based on 18 papers
Top 1%
0.7%